Capivasertib Cost-Effectiveness in Advanced Breast Cancer

By Rene Pretorius

April 18, 2025

Capivasertib, a novel AKT inhibitor, has gained approval as a second-line therapy for advanced breast cancer, but its high cost has sparked concerns about its economic viability. This review summarizes the results of the first published economic evaluation of Capivasertib in a cost-effectiveness study among patients with PIK3CA/AKT1/PTEN-altered, hormone receptor-positive (HR+), HER2-negative advanced breast cancer.

Key Insights:

  • The study used a Markov model to compare three treatments. These included capivasertib plus fulvestrant for all patients, for postmenopausal women only, and fulvestrant alone.
  • The incremental cost-effectiveness ratio for capivasertib plus fulvestrant was $280,854 per QALY. This exceeds the $100,000/QALY threshold.
  • To be cost-effective, capivasertib’s price would need a 70% reduction, lowering it to $7,000 per cycle.

Evaluating Capivasertib´s Economic Value

The study evaluates capivasertib combined with fulvestrant for advanced breast cancer. It compares three approaches: capivasertib with fulvestrant for all patients, only for postmenopausal women, or fulvestrant alone. The model uses a U.S. payer perspective with 2023 dollars. It measures benefits in life years and quality of life over a patient’s lifetime. Multiple scenarios confirm the findings’ reliability. Adding capivasertib for all patients increases costs by $410,765 and extends quality life by 1.46 years. This yields a cost of $280,854 per quality life year gained. Restricting capivasertib to postmenopausal women proved less effective and remained overly expensive. These conclusions were consistent across multiple tested scenarios.

Pricing and Access Implications

Capivasertib’s high price creates access barriers for advanced breast cancer treatment. Its cost-effectiveness ratio of $280,854 per quality-adjusted life year exceeds the $100,000 threshold. This makes it unaffordable for many payers. A 70% price cut to $7,000 per cycle could align costs with benefits. This would improve access for patients with PIK3CA/AKT1/PTEN-altered, HR+/HER2− breast cancer. High costs may reduce use, especially in resource-limited settings. This could widen treatment disparities. Payers and manufacturers should consider value-based pricing or patient assistance programs to enhance affordability while leveraging the drug’s benefits.

In summary, capivasertib offers clinical value but costs too much. Pricing changes are essential to broaden access to this therapy.

For more details, refer to the study in SpringerLink.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.